Medtech Looks Expensive But Remains a Trade War Safe Haven
This article is for subscribers only.
Makers of medical devices and diagnostics that have been more immune to the latest twists and turns of the ongoing U.S.-China trade war are more expensive than peers, but that may be for a good reason.
A steady outlook for devices, paired with the group’s role as a “safe haven in choppy global markets,” should keep investors interested despite near-record multiples, according to a research note published by Jefferies analysts led by Raj Denhoy.